澳门在线赌城娱乐 today announced the successful completion of an equity investment with Cellectis, a clinical-stage biotechnology company.
The equity investment and a research collaboration agreement, announced in 2023年11月 will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design up to 10 novel cell and gene therapy products for areas of high unmet need, 包括肿瘤, 免疫学和罕见疾病.
金融方面的考虑
2023年第四季度, Cellectis received an initial payment of $105m from 澳门在线赌城娱乐, which comprised a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment.
An additional $140m equity investment, 5美元/股, has closed following the satisfaction of customary closing conditions including Cellectis shareholders’ approval and regulatory clearances. Post-closing of this second investment, 澳门在线赌城娱乐 holds a total equity stake of c.44%是凯尔特人. 澳门在线赌城娱乐 expects to continue to treat its investment in Cellectis as an associate.
Under the terms of the research collaboration, Cellectis is also eligible to receive an investigational new drug (IND) option fee and 发展, regulatory and sales-related milestone payments, 从7000万美元到2.2亿美元不等, per each of the 10 candidate products, 加上分级版税.
澳门在线赌城娱乐 retains an option for a worldwide exclusive license for the candidate products developed under the research collaboration agreement, to be exercised before IND filing.
笔记
Alexion
Alexion, 澳门在线赌城娱乐 罕见的疾病 is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, 发展 and delivery of life-changing medicines. A pioneering leader in rare disease for more than three decades, Alexion was the first to translate the complex biology of the complement system into transformative medicines, and today it continues to build a diversified pipeline across disease areas with significant unmet need, using an array of innovative modalities. 作为澳门在线赌城娱乐的一部分, Alexion is continually expanding its global geographic footprint to serve more rare disease patients around the world. It is headquartered in Boston, US.
澳门在线赌城娱乐在 肿瘤学
澳门在线赌城娱乐 is leading a revolution in 肿瘤学 with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that 澳门在线赌城娱乐 has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
澳门在线赌城娱乐 has the vision to redefine cancer care and, 有一天,, eliminate cancer as a cause of death.
澳门在线赌城娱乐
澳门在线赌城娱乐 (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, 发展, and commercialisation of prescription medicines in 肿瘤学, 罕见疾病, 和澳门第一赌城在线娱乐, 包括心血管, 肾 & 新陈代谢和呼吸 & 免疫学. 总部设在剑桥, UK, 澳门在线赌城娱乐 operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 请访问 澳门在线赌城娱乐.com and follow the Company on social media @澳门在线赌城娱乐
联系人
For details on how to contact the 投资者关系 Team, please click 在这里. 对于“媒体联系人”，单击 在这里.
艾德里安·坎普
公司秘书
澳门在线赌城娱乐